ProPhase Labs (PRPH) announced the successful completion of a key validation study evaluating the performance of the BE-Smart molecular diagnostic test compatibility with samples obtained from esophageal brush cytology. The study demonstrated BE-Smart achieved greater than a 95% technical success rate, confirming the BE-Smart’s ability to reliably and accurately detect our panel of biomarkers, designed to assess progression risk in Barrett’s esophagus and other distal esophageal conditions. Prophase will now move to accelerated commercialization of BE-Smart with expected clinical launch in the next 2-3 quarters.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRPH:
- ProPhase Labs announces formation of Clinical Science Advisory Board
- ProPhase Labs’ Earnings Call: Strategic Moves Amid Challenges
- ProPhase Labs Reports Q1 2025 Earnings and Strategic Developments
- ProPhase Labs says CEO voluntarily agrees to defer salary by over two thirds
- ProPhase Labs expects to receive 6-month extension for Nasdaq listing